9/7/2007

Edwards Lifesciences Corp. received European approval to market its Edwards Sapien transcatheter aortic heart valve technology with the RetroFlex transfemoral delivery system. The valve, which is implanted through the leg in a minimally invasive procedure, is for patients with severe aortic heart valve stenosis who are not good candidates for conventional open-heart valve replacement surgery.

Related Summaries